2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The PET tracer \[F18\]-FDDNP has a specific affinity for lesions containing tau protein.

The study consists of two phases:

* In the first (cross-sectional) phase it will be assessed the uptake of \[18F\]-FDDNP in 10 cases with progressive supranuclear palsy (PSP, a tauopathy) en 10 with multi-system atrophy (MSA, a non-tauopathy), along with 20 individuals with Unclassifiable Parkinsonism, as previously defined in a European cohort study.
* In the second (longitudinal) phase it will be prospectively followed the 20 unclassifiable patients (at 6, 12 and 18 months) by means of validated scales and accepted diagnostic criteria in order to try to correlate their eventual clinical diagnosis with baseline PET findings. On this basis, we endeavour to estimate the ability of this technique to detect in vivo underlying tau pathology in subjects initially unclassifiable on clinical grounds.

We hypothesized that:

1. Patients with clinically definite PSP will present an increased uptake in basal ganglia, brainstem and cerebellum.
2. Patients with clinically defined MSA will not present specific uptake.
3. Part of unclassifiable patients with parkinsonism will present a pattern of uptake similar to patients with clinically defined PSP and this part along the clinical follow-up will be meet clinical criteria for diagnose of PSP

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894

Alzheimer's Disease (AD) Parkinson's Disease (PD) Chronic Traumatic Encephalopathy (CTE) +4 more

COMPLETED PHASE1

Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes

NCT04557865

Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan

COMPLETED NA

Evaluation of [18F]APN-1607 as a PET Biomarker

NCT05005819

Progressive Supranuclear Palsy Healthy Volunteers

COMPLETED PHASE1

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503

Frontotemporal Lobar Degeneration Alzheimer Disease Cognitively Normal

RECRUITING PHASE3

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

NCT04251130

Mild Cognitive Impairment

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Progressive Supranuclear Palsy Multi-System Atrophy Parkinsonism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[F18]-FDDNP

2-(1-{6-\[(2-\[F-18\]fluoroethyl) (methyl)amino\]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel

Group Type EXPERIMENTAL

[F18]-FDDNP

Intervention Type DRUG

radiopharmaceutical tracer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[F18]-FDDNP

radiopharmaceutical tracer

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

22-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is male or female ≥ 40 years old;
* The individual has one of these three conditions:
* probable PSP according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS)
* probable MSA according to criteria of the Second consensus statement on the diagnosis of multiple system atrophy
* unclassifiable parkinsonism according to criteria defined by Katzenschlager et al, 2003:
* Patients with atypical parkinsonism without response to treatment with levodopa and does not meet any of the diagnostic criteria for other known atypical parkinsonism
* Patient given written consent

Exclusion Criteria

* The subject is diagnosed with Parkinson's Disease and meets the diagnostic criteria United Kingdom Parkinson's Disease Society Brain Bank -The subject is pregnant or breastfeeding;
* The subject has a history of drug abuse or alcohol;
* The subject has a moderate or severe renal function impairment (creatinine serum\> 1.5 mg / dL);
* The subject has a moderate or severe hepatic impairment (bilirubin\> 2 times the upper limit of normal, transaminases\> 3 times the limit top of normal);
* The subject presents structural abnormalities in the basal ganglia or cortical level on MRI or CT;
* The subject has participated in a clinical study with a pharmaceutical product investigation within 30 days prior to screening and / or a radiopharmaceutical minimum period of 5 radioactive half-lives prior to screening;
* Occupational exposure to radiation\> 15 milliSievert (mSv) / year
* Use of nonsteroidal antiinflammatory drug (NSAIDs), for some reason, can not be replaced by any other drug 4 weeks before the PET scan;
* The subject has allergy investigational product or any of its components;
* The subject has a clinically severe active disease, with a hope reduced life;
* The subject is claustrophobic / a.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No